South Korea · Delayed Price · Currency is KRW Daewon Pharmaceutical Statistics
Total Valuation
KRX:003220 has a market cap or net worth of KRW 168.25 billion. The enterprise value is 305.59 billion.
| Market Cap | 168.25B |
| Enterprise Value | 305.59B |
Important Dates
The next estimated earnings date is Thursday, August 13, 2026.
| Earnings Date | Aug 13, 2026 |
| Ex-Dividend Date | Dec 29, 2025 |
Share Statistics
KRX:003220 has 21.43 million shares outstanding. The number of shares has increased by 0.40% in one year.
| Current Share Class | 21.43M |
| Shares Outstanding | 21.43M |
| Shares Change (YoY) | +0.40% |
| Shares Change (QoQ) | +5.43% |
| Owned by Insiders (%) | 38.80% |
| Owned by Institutions (%) | 11.61% |
| Float | 12.98M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 8.92 |
| PS Ratio | 0.28 |
| PB Ratio | 0.62 |
| P/TBV Ratio | 0.85 |
| P/FCF Ratio | 12.79 |
| P/OCF Ratio | 3.83 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 12.86, with an EV/FCF ratio of 23.24.
| EV / Earnings | n/a |
| EV / Sales | 0.50 |
| EV / EBITDA | 12.86 |
| EV / EBIT | n/a |
| EV / FCF | 23.24 |
Financial Position
The company has a current ratio of 1.18, with a Debt / Equity ratio of 0.68.
| Current Ratio | 1.18 |
| Quick Ratio | 0.64 |
| Debt / Equity | 0.68 |
| Debt / EBITDA | 8.07 |
| Debt / FCF | 14.08 |
| Interest Coverage | -0.21 |
Financial Efficiency
Return on equity (ROE) is -1.82% and return on invested capital (ROIC) is 5.10%.
| Return on Equity (ROE) | -1.82% |
| Return on Assets (ROA) | -0.16% |
| Return on Invested Capital (ROIC) | 5.10% |
| Return on Capital Employed (ROCE) | -0.39% |
| Weighted Average Cost of Capital (WACC) | -24.41% |
| Revenue Per Employee | 472.07M |
| Profits Per Employee | -3.41M |
| Employee Count | 1,283 |
| Asset Turnover | 1.01 |
| Inventory Turnover | 3.08 |
Taxes
In the past 12 months, KRX:003220 has paid 5.41 billion in taxes.
| Income Tax | 5.41B |
| Effective Tax Rate | 1,425.80% |
Stock Price Statistics
The stock price has decreased by -40.63% in the last 52 weeks. The beta is 0.16, so KRX:003220's price volatility has been lower than the market average.
| Beta (5Y) | 0.16 |
| 52-Week Price Change | -40.63% |
| 50-Day Moving Average | 9,596.20 |
| 200-Day Moving Average | 11,404.90 |
| Relative Strength Index (RSI) | 40.05 |
| Average Volume (20 Days) | 342,533 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, KRX:003220 had revenue of KRW 605.66 billion and -4.38 billion in losses. Loss per share was -224.86.
| Revenue | 605.66B |
| Gross Profit | 271.77B |
| Operating Income | -1.54B |
| Pretax Income | 379.64M |
| Net Income | -4.38B |
| EBITDA | 22.94B |
| EBIT | -1.54B |
| Loss Per Share | -224.86 |
Balance Sheet
The company has 56.01 billion in cash and 185.21 billion in debt, with a net cash position of -129.20 billion or -6,028.03 per share.
| Cash & Cash Equivalents | 56.01B |
| Total Debt | 185.21B |
| Net Cash | -129.20B |
| Net Cash Per Share | -6,028.03 |
| Equity (Book Value) | 270.98B |
| Book Value Per Share | 12,263.15 |
| Working Capital | 37.03B |
Cash Flow
In the last 12 months, operating cash flow was 43.95 billion and capital expenditures -30.80 billion, giving a free cash flow of 13.15 billion.
| Operating Cash Flow | 43.95B |
| Capital Expenditures | -30.80B |
| Depreciation & Amortization | 24.48B |
| Net Borrowing | -1.69B |
| Free Cash Flow | 13.15B |
| FCF Per Share | 613.62 |
Margins
Gross margin is 44.87%, with operating and profit margins of -0.25% and -0.72%.
| Gross Margin | 44.87% |
| Operating Margin | -0.25% |
| Pretax Margin | 0.06% |
| Profit Margin | -0.72% |
| EBITDA Margin | 3.79% |
| EBIT Margin | -0.25% |
| FCF Margin | 2.17% |
Dividends & Yields
This stock pays an annual dividend of 250.00, which amounts to a dividend yield of 3.10%.
| Dividend Per Share | 250.00 |
| Dividend Yield | 3.10% |
| Dividend Growth (YoY) | -16.67% |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.40% |
| Shareholder Yield | 3.03% |
| Earnings Yield | -2.60% |
| FCF Yield | 7.82% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Analyst Forecast
The average price target for KRX:003220 is 14,666.67, which is 86.60% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | 14,666.67 |
| Price Target Difference | 86.60% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (3Y) | 6.29% |
| EPS Growth Forecast (3Y) | n/a |
Stock Splits
The last stock split was on March 7, 2022. It was a forward split with a ratio of 1.03.
| Last Split Date | Mar 7, 2022 |
| Split Type | Forward |
| Split Ratio | 1.03 |
Scores
KRX:003220 has an Altman Z-Score of 2.17 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.17 |
| Piotroski F-Score | 3 |